This video summarizes the underlying cause of hypertrophic cardiomyopathy (HCM), common symptoms of HCM, mechanism of action of mavacamten, and key results of the EXPLORER-HCM trial, which compared mavacamten to placebo in patients with obstructive HCM. The results of the EXPLORER-HCM study were recently published in the The Lancet. A plain language summary of the study has subsequently been published in Future Cardiology and helps patients, their caregivers, patient advocates and healthcare professionals understand the results of the trial.
Read the article ‘A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy’ at https://www.futuremedicine.com/doi/10.2217/fca-2021-0044
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Iacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa et al.
The Lancet 396(10253), 759-769 (2020) DOI: 10.1016/S0140-6736(20)31792-X